🟢 Bayer Aktiengesellschaft is trading 3.6% up today after FDA approval of MRI contrast agent Ambelvist

Bayer Aktiengesellschaft is trading 3.6% up today at $37.44 following the FDA approval of its new MRI contrast agent, Ambelvist (gadoquatrane).

• The June 16, 2026, regulatory win positions Ambelvist as the lowest-dose macrocyclic gadolinium-based agent, significantly expanding the company's radiology portfolio.
• This positive catalyst is lifting investor sentiment around the pharmaceutical pipeline, helping to offset broader concerns regarding ongoing litigation and operational headwinds.
• The stock is extending gains as the market reacts to the successful expansion of Bayer's specialized medical imaging offerings.